Karen MacDonald

17PUBLICATIONS
20CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsBiologically active moleculesHaematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Oct 03, 2024
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

Ivo Abraham, Matthias Calamia, Nimer Alkhatib

|Jul 17, 2024
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

Karen MacDonald, Marc Pondel, Ivo Abraham

|Jul 17, 2024
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.

Ivo Abraham, Matthias Calamia, Nimer Alkhatib

|Mar 15, 2024
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.

Karen MacDonald, Marc Pondel, Ivo Abraham

|Sep 29, 2022
Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?

Rebecca M Thiede, Mohammad Fazel, Karen M MacDonald

|Dec 07, 2021
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.

Ivo Abraham, Uchenna Onyekwere, Baris Deniz

Pageof 3

Frequent Collaborators

13 joint publications

Ivo Abraham

4 joint publications

Marc Pondel

4 joint publications

Ali McBride

4 joint publications

Ivo Abraham